KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Current Liabilities: 2010-2024

Historic Total Current Liabilities for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $309.9 million.

  • Pacira BioSciences' Total Current Liabilities fell 65.05% to $107.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.1 million, marking a year-over-year decrease of 65.05%. This contributed to the annual value of $309.9 million for FY2024, which is 218.25% up from last year.
  • Per Pacira BioSciences' latest filing, its Total Current Liabilities stood at $309.9 million for FY2024, which was up 218.25% from $97.4 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Total Current Liabilities ranged from a high of $521.1 million in FY2021 and a low of $97.4 million during FY2023.
  • For the 3-year period, Pacira BioSciences' Total Current Liabilities averaged around $185.0 million, with its median value being $147.8 million (2022).
  • As far as peak fluctuations go, Pacira BioSciences' Total Current Liabilities plummeted by 71.64% in 2022, and later surged by 218.25% in 2024.
  • Pacira BioSciences' Total Current Liabilities (Yearly) stood at $253.3 million in 2020, then soared by 105.71% to $521.1 million in 2021, then crashed by 71.64% to $147.8 million in 2022, then tumbled by 34.10% to $97.4 million in 2023, then surged by 218.25% to $309.9 million in 2024.